A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

July 1, 2022

Study Completion Date

November 1, 2022

Conditions

Healthy

Interventions

DRUG

Tacrolimus

Tacrolimus 5mg (1 mg \* 5 capsules)

DRUG

IN-A001(Tegoprazan)

IN-A001 50mg(Tegoprazan 50mg\* 1 tablet)

DRUG

IN-A001(Tegoprazan) + Tacrolimus

IN-A001 50mg(Tegoprazan 50mg\*1 tablet) and Tacrolimus 5mg(1mg \* 5capsules)

Trial Locations (1)

Asan Medical Center, Seoul